Companies / Vivos Therapeutics, Inc.

Vivos Therapeutics, Inc.

Nasdaq: VVOSCIK 1716166LITTLETON, CO

Financials · FY2025

Revenue$17.44M
Net income$-21.23M
Total debt$617.0K
Cash$2.11M
Diluted EPS$-2.07
Shares outstanding13.9M

Ownership

13.9M shares outstanding · as of May 20, 2026
5.0%Institutions
Ownership
Institutions5.02%697,357
Public float94.98%13,197,243

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 1

View all →
Insider% of sharesShares
Johnson Gregg CDirector
——

Institutional holders 21

View all →
HolderValue% of shares
Vanguard Group Inc$617.4K2.19%
DRW Securities, LLC$235.3K0.83%
Geode Capital Management, LLC$112.7K0.69%
B. Riley Wealth Advisors, Inc.$88.4K0.31%
Commonwealth Equity Services, LLC$82.2K0.29%
Acorn Wealth Advisors, LLC$30.0K0.11%
UBS Group AG$25.7K0.09%
Northern Trust Corp$25.4K0.09%
BlackRock, Inc.$12.6K0.20%
State Street Corporation$11.3K0.18%

Activity

Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).
DateActorActionSecurityValueShares ΔPosition afterImpact
Q1 2026
as of
Geode Capital Management, LLC
13F manager
AddCommon Stock$46.3K+39K
+69.74%
95,543
0.69% of shares
low
Q4 2025
as of
Bank of America Corp /De
13F manager
AddCommon Stock$30+15
+12.82%
132
<0.01% of shares
low
Q1 2026
as of
Northwestern Mutual Wealth Management Co
13F manager
NewCommon Stock$4+3
3
<0.01% of shares
low
Q1 2025
as of
Barclays PLC
13F manager
NewCommon Stock$3+1
1
<0.01% of shares
low
Q2 2025
as of
Barclays PLC
13F manager
ExitCommon Stock$-3-1
-100.00%
—
low

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
VVOSCommon StockEquity92859E207BBG00H1NZV76